Bristol Myers Squibb (BMY) Construction in Progress (2015 - 2026)
Bristol Myers Squibb (BMY) reported Construction in Progress of $1.5 billion for Q1 2026, down 6.94% year-over-year from $1.7 billion in Q1 2025, and down 4.82% on a QoQ basis from $1.6 billion in Q4 2025.
Bristol Myers Squibb (BMY) has 12 years of Construction in Progress data on file, last reported at $1.5 billion in Q1 2026.
- Quarterly Construction in Progress fell 6.94% year-over-year to $1.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (down 6.94% YoY) and the FY2025 annual result came in at $1.6 billion, up 6.16% from the prior year.
- Construction in Progress retreated to $1.5 billion in Q1 2026 per BMY's latest filing, from $1.6 billion in the prior quarter.
- Across five years, Construction in Progress topped out at $1.8 billion in Q2 2025 and bottomed at $800.0 million in Q1 2022.
- The 5-year median for Construction in Progress is $1.2 billion (2024), against an average of $1.3 billion.
- The widest annual swing landed in 2022, when Construction in Progress jumped 54.14%; it then slipped 6.94% in 2026.
- Tracing BMY's Construction in Progress over 5 years: stood at $1.1 billion in 2022, then advanced by 2.09% to $1.1 billion in 2023, then surged by 41.86% to $1.5 billion in 2024, then advanced by 6.16% to $1.6 billion in 2025, then dropped by 4.82% to $1.5 billion in 2026.
- Per Business Quant, the three latest BMY Construction in Progress figures stand at $1.5 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.5 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 1.54 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.54 Bn |
| Dec 31, 2025 | 1.62 Bn |
| Sep 30, 2025 | 1.46 Bn |
| Jun 30, 2025 | 1.76 Bn |
| Mar 31, 2025 | 1.66 Bn |
| Dec 31, 2024 | 1.53 Bn |
| Sep 30, 2024 | 1.37 Bn |
| Jun 30, 2024 | 1.26 Bn |
| Mar 31, 2024 | 1.21 Bn |
| Dec 31, 2023 | 1.08 Bn |
| Sep 30, 2023 | 1.11 Bn |
| Jun 30, 2023 | 1.20 Bn |
| Mar 31, 2023 | 1.07 Bn |
| Dec 31, 2022 | 1.05 Bn |
| Sep 30, 2022 | 973.00 Mn |
| Jun 30, 2022 | 850.00 Mn |
| Mar 31, 2022 | 800.00 Mn |
| Dec 31, 2021 | 764.00 Mn |
| Sep 30, 2021 | 695.00 Mn |
| Jun 30, 2021 | 565.00 Mn |
| Mar 31, 2021 | 519.00 Mn |
| Dec 31, 2020 | 487.00 Mn |
| Sep 30, 2020 | 409.00 Mn |
| Jun 30, 2020 | 422.00 Mn |
| Mar 31, 2020 | 456.00 Mn |
| Dec 31, 2019 | 527.00 Mn |
| Sep 30, 2019 | 465.00 Mn |
| Jun 30, 2019 | 453.00 Mn |
| Mar 31, 2019 | 477.00 Mn |
| Dec 31, 2018 | 548.00 Mn |
| Dec 31, 2017 | 980.00 Mn |
| Dec 31, 2016 | 849.00 Mn |
| Dec 31, 2015 | 662.00 Mn |